Pulmonary arterial hypertension associated with chronic hemolytic anemia

Pulmonary arterial hypertension associated with chronic hemolytic anemia (PAH-CHA) is a form of pulmonary hypertension that develops as a complication of chronic red blood cell destruction (hemolysis). It is classified within Group 5 of the clinical classification of pulmonary hypertension, specifically as a condition where pulmonary vascular disease arises in the setting of hematological disorders. Chronic hemolytic anemias that may lead to this condition include sickle cell disease, thalassemia, hereditary spherocytosis, and other disorders characterized by ongoing red blood cell breakdown. The underlying mechanism involves chronic hemolysis releasing free hemoglobin into the plasma, which scavenges nitric oxide — a key molecule for blood vessel relaxation — leading to endothelial dysfunction, vasoconstriction, and progressive remodeling of the pulmonary arteries. The condition primarily affects the cardiovascular and pulmonary systems. Key symptoms include progressive shortness of breath (dyspnea), particularly during physical exertion, fatigue, exercise intolerance, chest pain, and in advanced cases, signs of right heart failure such as peripheral edema, abdominal distension from ascites, and syncope (fainting). Patients may also exhibit symptoms related to their underlying hemolytic anemia, including jaundice, pallor, and splenomegaly. Diagnosis typically involves echocardiography for screening, with confirmation by right heart catheterization demonstrating elevated pulmonary arterial pressures. The treatment landscape for PAH-CHA remains challenging and is not as well established as for idiopathic PAH. Management focuses on treating the underlying hemolytic condition (e.g., hydroxyurea or transfusion therapy in sickle cell disease), optimizing oxygen delivery, and cautious use of pulmonary vasodilator therapies. Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs have been used in some patients, though evidence for their efficacy in this specific population is limited compared to other forms of PAH. Supportive care including diuretics for fluid management and anticoagulation in selected patients may also be employed. Prognosis varies depending on the severity of the underlying hemolytic disorder and the degree of pulmonary vascular involvement.

Common questions about Pulmonary arterial hypertension associated with chronic hemolytic anemia